Neuralink Launches Clinical Trial in Britain to Test Brain Chip
The trial will evaluate the safety and functionality of the device in as many as seven patients who have neurological conditions that impair their ability to use electronics, according to an announcement from University College London Hospitals, one of the research sites.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist. IBI3032 is an orally administered small-molecule GLP-1 receptor agonist with bias for cAMP signaling pathway, discovered and developed by Innovent Biologics with proprietary rights. Preclinical data demonstrate its superior pharmacokinetic (PK) and physicochemical properties compared to peer compounds. In animal models, IBI3032 achieved 5 to 10 times higher oral exposure at equivalent doses, with improved efficacy and good tolerability in both GLP-1R KI DIO mice and obese monkey models, achieving comparable therapeutic effects at lower doses. The Phase 1 clinical trials of IBI3032 are planned to be conducted concurrently in China and the U.S. Dosing in healthy volunteers and overweight or obese participants is expected to begin in the second half of 2025. Innovent is building up its CVM pipeline with mazdutide as the cornerstone, and the initiation of the IBI3032 clinical study marks a significant step in the evolution of its CVM pipeline portfolio with global potential. Dr. Lei Qian, Chief R&D Officer for General Biomedicines Pipeline at Innovent Biologics, said, "GLP-1 has emerged as a blockbuster target over the past decade. Its oral form, with its convenience, flexibility, and unique advantage in combination treatment strategies, holds promise as a differentiated complement to GLP-1R-targeting biologicals. Beyond traditional applications in diabetes and weight management, oral GLP-1 possess potential in treating related diseases such as hypertension and OSA (obstructive sleep apnea). IBI3032 has demonstrated its promising efficacy profiles in animal models, where IBI3032 exhibited a longer elimination half-life and higher drug exposure levels than its competitors at the same dose. We are excited to advance this candidate into clinical development. This IND approval reflects Innovent's strong R&D capabilities and, most importantly, our commitment to global innovation. We hope that in the near future, IBI3032 can offer more effective and convenient treatment options to benefit patients around the world. " About IBI3032 IBI3032 is a novel oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA). By efficiently and selectively targeting GLP-1R, it activates downstream signal transduction, thereby delaying gastric emptying, inhibiting appetite, and promoting insulin secretion, and ultimately supporting the treatment of insulin-related metabolic diseases such as obesity and T2DB. Discovered through a structure-based drug design (SBDD) strategy combined with systematic physicochemical property optimization, IBI3032 has shown better PK and physicochemical properties compared to similar compounds. The IND application of IBI3032 was accepted by China's National Medical Products Administration (NMPA) and approved by the U.S. Food and Drug Administration (FDA). A multi-regional Phase 1 clinical study of IBI3032 is planned for initiation in the second half of 2025. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: （1）Innovent does not recommend the use of any unapproved drug (s)/indication (s). （2）Ramucirumab (Cyramza)，Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
What we know about electric car grants worth £1,500 as first eligible EV models confirmed
The government has unveiled a series of Citroen models eligible under the government's new £650 million electric car grants scheme. The first electric car models eligible for the government's new £650 million electric car grants have been announced. Drivers will be able to save £1,500 with the purchase of new Citroen e-C3, e-C4, e-C5 and e-Berlingo cars, the Department for Transport (DfT) said. The discount will be automatically applied at the point of sale, and will enable motorists purchasing a new electric car to save either £1,500 or £3,750, depending on sustainability criteria. The government's vow to make it cheaper to buy an electric car comes as part of its goal of banning the sale of new fully petrol or diesel cars and vans from 2030. Transport Secretary Heidi Alexander said: 'With the first four models approved today, and more to come over the next few weeks, this summer we're making owning an electric car cheaper, easier and a reality for thousands more people across the UK." Under the government's zero emission vehicle (Zev) mandate, at least 28% of new cars sold by each manufacturer in the UK this year must be zero emission, which generally means pure electric. Across all manufacturers, the figure during the first half of the year was 21.6%. Alexander has already announced £63m worth of funding to boost charging infrastructure, including £25m of support for local authorities to provide at-home charging for motorists who don't have driveways. Another £8m will be spent on powering electric ambulances and medical fleets across 200 sites within the NHS, while road signs for EV charging hubs will be introduced on major A-roads in England. What do we know about the new subsidies for EV drivers? The grants will be funded through a new £650m scheme announced on 14 July, which will be restricted to vehicles priced up to £37,000. The Department for Transport (DfT) said at the time that 23 new models were available for less than £30,000. Amounts given will be based on a car's 'sustainability criteria', the DfT said, with the greenest vehicles placed in band one, meaning a grant of up to £3,750. Band two vehicles will receive up to £1,500. Edmund King, AA president, said: 'This discount of £1,500 for some more affordable EVs will help a number of those with tighter budgets. We look forward to seeing the full list of discounts up to £3,750 on more models to really push the market forward.' Ian Plummer, commercial director of online vehicle marketplace Auto Trader, previously said 'any incentives' to help people buy an electric car are welcome as many drivers are 'put off by the high upfront cost'. Prior to the government's announcement, The Telegraph reported that the grants would provide a huge boost for Nissan, which has a plant in Sunderland, but would be unlikely to help Tesla, whose cars are generally beyond the scheme's price range. How many people are buying EVs? In the first half of this year, electric car sales in the UK increased by a third, according to figures from the Society of Motor Manufacturers and Traders (SMTT) lobby group. Sales of battery electric cars rose by 34.6% to 224,838 vehicles between the start of January and the end of June. Of the 191,200 cars sold in the UK in June, a quarter (almost 47,400) were electric vehicles. The government wants to phase out the sale of new petrol and diesel cars from 2030 onwards, although hybrids can be sold until 2035. It says all new cars and vans will have to be 100% zero emission by 2035. How much more expensive are electric cars to buy? The average cost to buy an electric car in the UK is currently about £46,000, according to financial researchers NimbleFins, although it says that prices range from £14,995 (for a Dacia Spring Electric) to as much as £330,000 for a Rolls-Royce Spectre. Among luxury electric brands such as Tesla, Porsche, Audi, Jaguar and Mercedes, the average cost is about £69,000, while a non-luxury EV is about £33,000 on average. NimbleFins said the cost of an average small car is about £22,000, rising to £27,000 for a medium-sized car and £35,000 for an SUV, inclusive of petrol and electric models. The Electric Car Scheme says the average petrol car costs £21,964, compared to about £49,000 for an EV. How much do electric vehicles cost to run? The average cost of running a car in the UK is £3,357, according to NimbleFins. This includes fuel, car insurance, repairs, road tax and the purchase or depreciation per year. It said that despite electricity prices currently being high, fuel costs much less with an EV than a petrol or diesel engine. The average cost for a mile of driving is about 7p on a standard electricity tariff or as low as 2p per mile on a time of use EV tariff, charging the vehicle at off-peak times, such as during the night. For a petrol or diesel car, NimbleFins says the cost of fuel per mile can be anything between 13p and 17p. The Electric Car Scheme says drivers of EVs can save up to £1,500 per year over 10,000 miles in fuel costs than with a petrol or diesel. Read more Major problem with plan to let EV drivers charge outside their homes (BristolLive) China's electric car revolution hammers demand for oil (The Telegraph) Volkswagen reports electric vehicles sales surge in 2025 (DW)
Yahoo
2 hours ago
- Yahoo
Musk's new pay package removes overhang for Tesla stock: Wedbush's Ives
-- According to Wedbush analyst Dan Ives in a note Monday, Tesla's new pay package for CEO Elon Musk eliminates a major uncertainty for the stock and sets the stage for long-term stability. In a note published after Tesla (NASDAQ:TSLA) filed an 8-K this morning, Wedbush called the Board's approval of a 96 million share restricted stock grant 'a strategic move' that will help retain Musk as Tesla's CEO through at least 2030. The award, recommended by a special committee of disinterested directors, comes under the 2019 Equity Incentive Plan and is equivalent to roughly one-third of the compensation earned under Musk's 2018 plan. 'This grant will now keep Musk as CEO of Tesla at least until 2030 and removes an overhang on the stock,' Wedbush said. 'Musk remains Tesla's big asset and this comp issue has been a constant concern of shareholders once the Delaware soap opera began.' According to Wedbush, Musk must pay Tesla $23.34 per share of restricted stock that vests, the same as the 2018 CEO Award's exercise price. The grant has an accounting fair value of about $23.7 billion. Wedbush said the package aligns with the firm's early July recommendation that Tesla's board 'step in to ensure Musk would commit to Tesla over the next few years.' 'With the AI talent war now fully underway across Big Tech, we believe this was a strategic move to keep TSLA's top asset,' Wedbush wrote. 'This framework for Musk's pay package and greater voting control removes a major overhang on the story.' Wedbush reiterated its Outperform rating and $500 price target on Tesla. Related articles Musk's new pay package removes overhang for Tesla stock: Wedbush's Ives Apollo economist warns: AI bubble now bigger than 1990s tech mania 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Sign in to access your portfolio
